Rationale for Ozekibart Plus Chemotherapy for Relapsed Ewing Sarcoma

Rashmi Chugh, MD, of the University of Michigan, discusses the clinical rationale and study background for an ongoing trial evaluating ozekibart, an innovative monoclonal antibody, in combination with the chemotherapy agents temozolomide and irinotecan for patients with Ewing sarcoma. Ewing sarcoma is a highly aggressive bone and soft tissue cancer that predominantly affects children, adolescents, and young adults. Although initial treatment regimens can be effective, patients who experience a relapse or whose disease becomes refractory to standard therapies face a significantly poorer prognosis. This creates an urgent clinical need for novel therapeutic strategies that can overcome resistance and improve survival outcomes.

In this phase 1 trial (NCT03715933), ozekibart is paired with the established chemotherapy duo of temozolomide and irinotecan. This combination is a frequently utilized second-line or third-line regimen in the sarcoma community, known for its ability to stabilize disease, though its long-term efficacy as a standalone treatment remains limited.

The study background is rooted in the hypothesis that adding ozekibart to this backbone will result in a synergistic effect. Researchers are interested in whether the addition of this targeted antibody can enhance the DNA-damaging effects of the chemotherapy or prevent the tumor cells from repairing themselves effectively. By integrating a targeted metabolic inhibitor with traditional cytotoxic drugs, the trial aims to move toward a more sophisticated, multi-pronged approach to treating relapsed Ewing sarcoma.

The goals of the study include the safety and recommended dose of ozekibart; in early findings, it also demonstrated a favorable response rate in these pretreated patients.

Chugh emphasizes that this study is a vital step in determining if modulating the metabolic environment of the tumor can provide the necessary breakthrough for a patient population that currently has very few effective therapeutic options. The trial is meticulously designed to monitor safety while assessing whether this novel triplet therapy can offer a durable response for those facing advanced disease.